Scott Gottlieb, MD, on Tuesday filed an ethics disclosure form with HHS, highlighting measures he would take to distance himself from the drug industry if confirmed to lead the Food and Drug Administration, reports Reuters.
Here are six things to know:
1. Dr. Gottlieb currently serves — or has served — on eight boards for various drug and healthcare companies. He's consulted for drugmakers like Roche or Eli Lilly and is a partner at a venture capital firm that's invested in 188 healthcare companies. From 2013 through 2015, Dr. Gottlieb received nearly $414,000 in payments from drug companies for data, speeches, consulting, travel and meals, according to federal open payments data.
2. Dr. Gottlieb said he is willing to resign from all outside boards and forfeit his consulting positions, according to The New York Times.
3. He also said he would divest his holdings for about 20 small healthcare organizations.
4. As FDA commissioner, Dr. Gottlieb said he would recluse himself from all regulatory decisions involving companies he's received payments from or held a financial interest in for one year.
5. He would also resign from his role at the investment firm and halt any consulting work while heading the FDA, reports Reuters.
6. Dr. Gottlieb's confirmation hearing is scheduled for April 5.
More articles on supply chain:
Mylan's underpayments to CMS in EpiPen rebate scandal likely exceed settlement amount, study finds
Supply chain tip of the week: Avoid hidden costs in prepackaged supplies
3 ways payers and providers can collaborate to lower drug costs